Answers are grounded in this paper and cite their sources.
Surprising results have been reported recently on the use of structured treatment interruptions (STIs) in two different situations in the management of HIV-1 infection. Interrupting therapy when the CD4+ T-lymphocyte count is below 350 cells/mm3 in order to reduce drug exposure was found to increase not only the risk of AIDS-related clinical events, but also the risk of cardiovascular and metabolic toxicities. This study called into question the use of the CD4+ T-cell-guided treatment interruption approach in this patient population. On the other hand, evidence was presented of the ability of STIs to enhance anti-HIV-specific immunity in patients with chronic HIV-1 infection. This resulted in a small, but significant, fraction of patients gaining the ability to maintain low plasma levels of HIV-1 RNA without the need for antiretroviral chemotherapy.
No takes yet. Share an insight, caveat, or question.
Jeffrey M. Jacobson (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: